PARAGON CARE LIMITED (PGC)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PGC - PARAGON CARE LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 4.88
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.50

21 Nov
2024

0.050

OPEN

$0.45

11.11%

HIGH

$0.50

3,415,769

LOW

$0.45

TARGET
$0.53

+0.04 change from previous day

 6.0% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PME . RMD . SOM . TRJ . UBI . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
PGC: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 0.9 2.3 xxx
DPS (cps) xxx N/A 0.0 xxx
EPS Growth xxx - 45.1% 100.0% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 22.7 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 18/09 - ex-div 0.6c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx0.9
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx2,969.9 M
Book Value Per Share xxxxxxxxxxxxxxx17.6
Net Operating Cash Flow xxxxxxxxxxxxxxx44.5 M
Net Profit Margin xxxxxxxxxxxxxxx0.28 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx3.13 %
Return on Invested Capital xxxxxxxxxxxxxxx2.18 %
Return on Assets xxxxxxxxxxxxxxx1.05 %
Return on Equity xxxxxxxxxxxxxxx3.13 %
Return on Total Capital xxxxxxxxxxxxxxx8.10 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx25.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx117 M
Long Term Debt xxxxxxxxxxxxxxx135 M
Total Debt xxxxxxxxxxxxxxx252 M
Goodwill - Gross xxxxxxxxxxxxxxx323 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx20 M
Price To Book Value xxxxxxxxxxxxxxx2.50

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx19.3 M
Capex % of Sales xxxxxxxxxxxxxxx0.65 %
Cost of Goods Sold xxxxxxxxxxxxxxx2,879 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx54 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx2 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.5

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

1

xxxxxxx xx xxx xxxx xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

22/11/2024

3

Downgrade to Hold from Buy

$0.52

4.00%

Bell Potter downgrades Paragon Care to Hold from Buy following the company's AGM update based on the stock's valuation.

The broker observes year-to-date revenue growth of 15.5% in FY25, with pharmacy revenue growth of 19.1% and complementary medicines up 17%. Service and surgical specialties experienced a decline in revenue.

Management provided "run rates" for the divisions, which the analyst views as guidance indications, although not explicitly stated as such. The run rates suggest revenue growth for Paragon of 8% in FY25, with gross margin slipping -60bps to 8.9%.

Cost-out guidance was retained at $5m in FY25 and $12m in FY26.

Bell Potter lowers the EPS forecast for FY25 by -2% and raises the FY26 EPS forecast by 1.3%. No change to the 52c target price.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of 2.40 cents.
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of 2.50 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

PGC STOCK CHART

FNArena News on PGC

1
FNArena Corporate Results Monitor – 02-09-2024

Sep 02 2024 - Australia
2
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
3
FNArena Corporate Results Monitor – 31-08-2023

Aug 31 2023 - Australia
4
Weekly Ratings, Targets, Forecast Changes – 28-07-23

Jul 31 2023 - Weekly Reports
5
Australian Broker Call *Extra* Edition – Mar 06, 2023

Mar 06 2023 - Daily Market Reports

Latest Medical Equipment & Devices News

1
ResMed’s Bounce-Back Complete

Oct 29 2024 - Australia
2
Dr Boreham’s Crucible: Pro Medicus

Sep 04 2024 - Australia
3
Pro Medicus: Don’t Stop Me Now

Aug 20 2024 - Technicals
4
Dr Boreham’s Crucible: Blinklab

May 20 2024 - Small Caps
5
ResMed Silences The Doubters

Apr 29 2024 - Australia
6
Dr Boreham’s Crucible: 4D Medical

Apr 23 2024 - Small Caps
7
Uptrend Resumed For ResMed

Mar 19 2024 - Technicals
8
Dr Boreham’s Crucible: Cochlear

Feb 28 2024 - Australia
9
Rudi Interviewed: Ongoing Potential In Technology & Growth

Feb 19 2024 - Rudi's View
10
Dr Boreham’s Crucible: Artrya

Feb 15 2024 - Small Caps